Quick Order

Human VEGFR3 / FLT-4 ELISA Kit

DatasheetComponentsSpecific ReferencesReviewsRelated Products
Principle Of The Test
Solid Phase Sandwich ELISA
Intended Use
For the quantitative determination of Human VEGFR3 / FLT-4 concentration in serum.
The use of this kit for other sample types need be validated by the end user due to the complexity of natural targets and unpredictable interference.
Assay Range
46.88-3000 pg/mL
Sensitivity
The minimum detectable dose of Human VEGFR3 / FLT-4 is typically less than 7.95 pg/mL. The MDD was determined by adding three standard deviations to the mean optical density value of twenty zero standard replicates and calculating the corresponding concentration.
Materials Provided
1. 96 well microplate coated with Capture Antibody
2. Detection Antibody conjugated to HRP
3. Standards
4. Wash Buffer Concentrate
5. Dilution Buffer Concentrate
6. Color Reagent A
7. Color Reagent B
8. Stop Solution
Storage
Unopened Kit: Store at 2 - 8℃
Opened/Reconstituted Reagents: Please refer to CoA
VEGFR3/FLT-4  Background

Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on.

Human VEGFR3/FLT-4  References
  • Shushanov S, et al. (2000)VEGFc and VEGFR3 expression in human thyroid pathologies. Int J Cancer.86(1): 47-52.
  • Iljin K, et al. (2001) VEGFR3 gene structure, regulatory region, and sequence polymorphisms. FASEB J. 15(6): 1028-36.
  • Liu XE, et al. (2004) Expression and significance of VEGF-C and FLT-4 in gastric cancer. World J Gastroenterol. 10(3): 352-5.
  • Stearns ME, et al. (2004) Expression of a flt-4 (VEGFR3) splicing variant in primary human prostate tumors. VEGF D and flt-4t(Delta773-1081) overexpression is diagnostic for sentinel lymph node metastasis. Lab Invest. 84(6): 785-95.
  • Size / Price
    Catalog: KIT10806-1
    List Price:   (Save )
    Price:      [How to order]
    AvailabilityIn StockShipping instructions
    Images
    • Human VEGFR3 / FLT-4 ELISA Kit, TYPICAL DATA
    • Human VEGFR3 / FLT-4 ELISA Kit, SPECIFICITY
    Recently Viewed Items
    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"